Author

Puja Kumari Agnivesh

National Institute of Pharmaceutical Education and ResearchORCID 0000-0002-2923-9328Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Microbiology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 2 Assay:metabolomics· 1

Frequent Co-Authors

Arnab RoyiD· 3 shared Nitin Pal KaliaiD· 3 shared Shashikanta SauiD· 3 shared Aman Dalal· 1 shared Anamika SharmaiD· 1 shared Deepak Kumar SharmaiD· 1 shared Harshada Anil BhaleraoiD· 1 shared Kishan Kumar Parida· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

Arnab RoyORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Exploiting NDH-2 Vulnerability: Quinolines as Antitubercular Agents

Shashikanta Sau, Rohit Kumar, Arnab Roy, Puja Kumari Agnivesh, Pallavi Saha, Harshada Anil Bhalerao, Rajesh Sonti, Deepak Kumar Sharma, Nitin Pal Kalia

This study identifies quinoline derivatives as antitubercular agents targeting NDH-2, showing efficacy against multidrug-resistant Mycobacterium tuberculosis.

bioRxiv · Jun 8, 2026 · PreprintMicrobiology

Repurposing ethacridine as a potent MMPL3 Inhibitor for the treatment of tuberculosis

Puja Kumari Agnivesh, Arnab Roy, Shashikanta Sau, Swati Meshram, Aman Dalal, Anamika Sharma, Nitin Pal Kalia

This paper identifies ethacridine as a potent inhibitor of MmpL3, effective against drug-sensitive and resistant tuberculosis strains.

bioRxiv · Nov 25, 2025 · PreprintMicrobiology

Targeting Metabolic Vulnerabilities: Valinomycin Augments the Potency of Bioenergetic Inhibitors in Combatting Drug-Resistant and Dormant Mycobacterium tuberculosis

Arnab Roy, Satish Kushwah, Shashikanta Sau, Puja Kumari Agnivesh, Kishan Kumar Parida, Madhe Divya, Nitin Pal Kalia

This study shows that valinomycin enhances the effectiveness of bioenergetic inhibitors against drug-resistant and dormant Mycobacterium tuberculosis by disrupting the proton motive force.

bioRxiv · Nov 23, 2025 · PreprintMicrobiology